Tempest Therapeutics secures exclusive rights to Senlang CAR-T platform outside China
TPST•Tempest Therapeutics exercised its option to license Senlang’s CD7-targeted lentiviral platform, securing exclusive development and commercialization rights outside China. The license covers in vivo CAR-T candidates, led by TPST-4903, and follows preliminary Phase 1 observations in 13 patients.
1. License rights secured
Tempest Therapeutics exercised its option to license Senlang’s CD7-targeted lentiviral platform, gaining exclusive development and commercialization rights outside China. The license covers in vivo CAR-T candidates, led by TPST-4903, a BCMA/GPRC5D dual-targeting treatment for relapsed or refractory multiple myeloma. Preliminary Phase 1 observations in 13 patients supported exercising the option, but additional follow-up is needed to assess benefits and risks. The agreement, originally announced in September 2026, includes financial obligations and development requirements.
